Press releases

May 20, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

May 14, 2025

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

Read more

May 07, 2025

Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference

Read more

May 06, 2025

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

Read more

April 30, 2025

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

Read more

April 22, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

March 19, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

February 24, 2025

Ultragenyx to Participate at Investor Conferences in March

Read more

February 19, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

February 18, 2025

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Read more